Cargando…
Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain
BACKGROUND AND PURPOSE: Programmed cell death protein-1 (PD1) expresses on the cell surface of the activated lymphocytes and at least a subset of Foxp3+ regulatory T cells. The binding of PD1 to its ligands including PD-L1 and PD-L2 leads to deliver an inhibitory signal to the activated cells. Altho...
Autores principales: | Khedri, Mostafa, Kooshki, Hamid, Taheri, Ramezan Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102928/ https://www.ncbi.nlm.nih.gov/pubmed/34084203 http://dx.doi.org/10.4103/1735-5362.310523 |
Ejemplares similares
-
Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer
por: Feng, Yanru, et al.
Publicado: (2022) -
Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury
por: Guo, Dongjun, et al.
Publicado: (2013) -
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020) -
Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
por: Gutic, Bojana, et al.
Publicado: (2023) -
Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)